Short Interest in Roche Holding AG (OTCMKTS:RHHBY) Decreases By 45.0%

Roche Holding AG (OTCMKTS:RHHBY - Get Free Report) was the target of a large decrease in short interest during the month of February. As of February 15th, there was short interest totalling 2,068,200 shares, a decrease of 45.0% from the January 31st total of 3,761,500 shares. Based on an average daily volume of 2,515,400 shares, the short-interest ratio is presently 0.8 days.

Roche Stock Performance

Shares of RHHBY stock traded up $0.09 during midday trading on Monday, reaching $41.83. 1,660,494 shares of the stock were exchanged, compared to its average volume of 2,896,557. Roche has a 1 year low of $29.20 and a 1 year high of $42.43. The company's 50 day moving average is $38.38 and its two-hundred day moving average is $38.41. The company has a quick ratio of 0.97, a current ratio of 1.26 and a debt-to-equity ratio of 0.86.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Minot DeBlois Advisors LLC purchased a new position in shares of Roche during the 4th quarter worth approximately $752,000. Hancock Whitney Corp grew its holdings in shares of Roche by 6.8% during the 4th quarter. Hancock Whitney Corp now owns 23,516 shares of the company's stock worth $820,000 after acquiring an additional 1,496 shares during the period. HighPoint Advisor Group LLC grew its holdings in shares of Roche by 2.8% during the 4th quarter. HighPoint Advisor Group LLC now owns 11,091 shares of the company's stock worth $387,000 after acquiring an additional 304 shares during the period. SVB Wealth LLC purchased a new stake in shares of Roche in the 4th quarter worth approximately $555,000. Finally, Altrius Capital Management Inc grew its stake in shares of Roche by 0.3% in the 4th quarter. Altrius Capital Management Inc now owns 183,448 shares of the company's stock worth $6,399,000 after buying an additional 603 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms have commented on RHHBY. Sanford C. Bernstein raised Roche to a "strong-buy" rating in a research report on Thursday, January 30th. Morgan Stanley began coverage on Roche in a research report on Wednesday, February 12th. They set an "equal weight" rating for the company. Finally, UBS Group raised Roche from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Roche presently has an average rating of "Hold".

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.